CANCER TARGETED TECHNOLOGY, LLC
Biotech · Private
PSMA-targeted small molecule drug conjugates (SMDCs) delivering MMAE payload to prostate cancer cells
- Grants
- $9.9M
- 10 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 25
- 3 granted · 22 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | $1,076,087 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of a Novel Prostate Cancer PET Diagnostic | $923,913 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a PSMA-Targeted Small-Molecule Drug Conjugate for Prostate Cancer | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | $1,375,908 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | $1,441,580 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of an Innovative PSMA-targeted Radiotherapy, CTT1403, in Prostate Cancer | $365,867 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | $1,000,002 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy | $999,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer | $1,999,998 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1642 | DOPHEN BIOMED, INC. | — | — |
| 1643 | T3S Technologies, Inc. | — | — |
| 1644 | MIDI, INC. | — | — |
| 1645 | CANCER TARGETED TECHNOLOGY, LLC | — | — |
| 1646 | IMMUNARTES LLC | — | — |
| 1647 | GENERAL NUTRACEUTICAL TECHNOLOGY LLC | — | — |
| 1648 | Boston Immune Technologies And Therapeutics Inc. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Phosphoramidate-based Psma-targeted Small-molecule Drug Conjugatesapplication
- Methods Of Treating Psma-positive Cancer Using Radionuclide Therapyapplication
- Chelated PSMA Inhibitorsapplication
- Chelated PSMA Inhibitorsgranted
- Albumin-Binding PSMA Inhibitorsgranted
- Chelated Psma Inhibitorsgranted
- Chelated Psma Inhibitorsapplication
- Methods of Treating Prostate Cancer Using Radionuclide Therapyapplication
- Chelated PSMA Inhibitorsapplication
- Albumin-binding Psma Inhibitorsapplication
- Chelated Psma Inhibitorsapplication
- Chelated PSMA Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.